CSIMarket Company Name, Ticker, Suppliers, else..
 
Accuray Incorporated  (NASDAQ: ARAY)
Other Ticker:  
 
 
Price: $2.0300 $-0.04 -1.932%
Day's High: $2.1 Week Perf: 0.00
Day's Low: $ 2.01 30 Day Perf: 12.78 %
Volume (M): 581 52 Wk High: $ 3.05
Volume (M$): $ 1,179 52 Wk Avg: $2.13
Open: $2.09 52 Wk Low: $1.40



 Market Capitalization (Millions $) 203
 Shares Outstanding (Millions) 100
 Employees 987
 Revenues (TTM) (Millions $) 433
 Net Income (TTM) (Millions $) -18
 Cash Flow (TTM) (Millions $) -30
 Capital Exp. (TTM) (Millions $) 5

Accuray Incorporated
Accuray Incorporated is a global provider of innovative precision radiation medicine solutions. The company was founded in 1990 and is headquartered in Sunnyvale, California, USA. The company's mission is to develop and deliver advanced radiation therapies that help people live longer, healthier lives.

Accuray's flagship product is the CyberKnifee System, which is the world's first and only robotic radiotherapy system designed to treat tumors anywhere in the body with sub-millimetric accuracy. The CyberKnife System uses advanced image guidance technology to track and adjust for the patient's breathing and movement, allowing for precise radiation delivery to the tumor while sparing surrounding healthy tissue.

The company also offers the TomoTherapye System, a comprehensive radiation therapy system that combines precise treatment delivery with integrated CT imaging to effectively target tumors while minimizing exposure to healthy tissue. The TomoTherapy System is used for the treatment of a wide range of cancers, including prostate, breast, lung, head and neck, and brain tumors.

In addition, Accuray provides quality assurance and service management solutions for radiation therapy clinics through its AQUAe software platform. AQUA provides real-time monitoring and reporting of treatment machine performance and maintenance to ensure that treatments are delivered accurately and safely.

Accuray has a global footprint, with offices in the Americas, Europe, and Asia. The company has a strong focus on research and development, and invests heavily in advanced technologies to improve cancer treatment outcomes. Accuray's products and solutions have been used to treat over a million patients worldwide.

Overall, Accuray's precision radiation medicine solutions offer patients better treatment options, improved outcomes, and a higher quality of life. The company's dedication to innovation and patient-centered care has positioned it as a leader in the radiation therapy industry.


   Company Address: 1240 Deming Way Madison 53717 WI
   Company Phone Number: 824-2800   Stock Exchange / Ticker: NASDAQ ARAY


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AONC        0.23% 
BSX        0.55% 
FONR   -1.77%    
ICAD        13.09% 
IMDS        13.09% 
ISRG   -0.5%    
• View Complete Report
   



Embecta Corp

Embecta Corp Reports Strong Q4 2024 Earnings bolstered by $21.60 Million Tax Provisions Amid Modest Revenue Growth

EMBC Reports Strong Earnings Despite Modest Revenue Growth in Q4 2024Embecta Corp (EMBC), a prominent player in the Medical Equipment and Supplies sector, has reported impressive earnings for the fourth quarter of 2024, showcasing a remarkable increase in earnings per share (EPS) despite relatively modest revenue growth. This performance highlights the company's ability to enhance profitability even in a challenging economic environment. Q4 Financial OverviewIn the fourth quarter of 2024, Embecta Corp achieved an EPS of $0.24, reflecting a remarkable year-over-year increase of 133.19%. This rise is noteworthy, given that it contrasts with a slight 1.847% increase in revenue, which reached $286.80 million compared to the same period in the prior year. However, compared to the previous financial quarter, EPS saw a marginal decline of 2.73% from $0.25 per share, while revenue surged by a healthy 5.402% from $272.10 million.
Lakeland Industries Inc

Lakeland Industries Inc Reports Strong Growth in Q3 2024: Positive Results from August to October

Lakeland Industries Inc announced EPS of $0.01 and Revenue of $38.51 million in its third quarter of 2025 financial report, company's income fell sharply $0.01 per share, versus $0.34 eps, earned in the corresponding three months a year before, although Lakeland Industries Inc saw its Revenue rise by 44.457 % in the corresponding period. Medical Equipment and Supplies company's revenue, advancement in the third quarter of 2025 correlates advantageously to its Medical Equipment and Supplies industry peers, which reported on average 1.68 % top-line rise in the same period yet.

Patterson Companies Inc

Patterson Companies Inc. Reports Smart Revenue Boost: A Promising Quarter from August to October 2024

Revenue improvement of 1.336 %, could not prevent income reduction of -28.57 % in the August to October 26 2024 time-frame, relative to similar quarter a year ago. revenue were at $1.67 billion and eps at $0.30.

Becton Dickinson And Company

Becton Dickinson's Profits Skyrocket 272.69% in Q4 2024: A Record-Breaking Surge!

Becton Dickinson and Company: A Robust Performer in the Medical Equipment and Supplies SectorBecton Dickinson and Company (BDX), a significant player in the medical equipment and supplies industry, demonstrated remarkable resilience and growth in its financial performance for the fourth quarter of 2024. As one of the leading global innovators in medical technology, BDX?s strong results relative to its peers underscore its operational excellence and innovative product offerings. Strong Q4 PerformanceIn the fourth quarter of 2024, Becton Dickinson reported earnings per share (EPS) of $1.37, reflecting an extraordinary increase of 272.69% compared to the same quarter the previous year. The company's revenue climbed to $5.44 billion, marking a growth of 6.88%. This growth trajectory is particularly noteworthy when contrasted with the broader Medical Equipment and Supplies sector, which saw an average top-line growth of only 1.12% during the same period.
Medtronic Plc

Medtronic Plc Reports a Significant Revenue Surge in Q2 2025 Earnings Season

For the most recent fiscal period Medtronic Plc profit per share jumped by 45.59 % of $0.99 per share compare to $0.68 a year before and bottom-line grew by 23.75 % from $0.80 per share from the previous reporting period. The Revenue grew by 5.248 % to $8.40 billion from $7.98 billion in the same reporting period a year before and sequentially revenue grew by 6.166 % from $7.92 billion.







Accuray Incorporated's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com